Skip to main content


  • Meeting abstract
  • Open Access

Clinical significance of CADM1/TSLC1/IgSF4 expression in Adult-T cell leukemia/lymphoma (ATLL): identification of various types of ATLL cells

  • 1,
  • 1,
  • 1,
  • 1,
  • 2,
  • 3,
  • 1,
  • 1,
  • 1,
  • 1,
  • 4,
  • 4 and
  • 1Email author
Retrovirology20118 (Suppl 1) :A49

  • Published:


  • Lymphoma
  • Adhesion Molecule
  • Cell Adhesion Molecule
  • Cell Fraction
  • Abnormal Lymphocyte

Cell adhesion molecule 1 (CADM1/TSLC1/IgSF4) was recently identified as a novel cell surface maker for adult T-cell leukemia/lymphoma (ATLL). In this manuscript, we developed several kinds of antibodies for diagnostic tools identifying CADM1-positive ATLL cells. 107 kDa of CADM1 protein was detected in the ATLL cell lines and a 72 kDa of soluble CADM1 protein was detected in serum from ATLL patients. In analysis by flow cytometry, percentages of CADM1+/CD4+ positive (DP) cells in the peripheral blood are well correlated with the percentages of CD4+/CD25+ DP cells in the peripheral bloods from various types of ATLL patients and HTLV-1 carriers. Percentages of CADM1+/CD4+ DP cell fraction were well correlated with the percentages of abnormal lymphocytes and DNA copy numbers of HTLV-1 infected or ATLL cells in the peripheral blood, particularly, with high DNA copy numbers of HTLV-1-infected lymphocytes from HTLV-1 carriers. Expression of soluble-form CADM1 is also detected in the peripheral blood from acute-type of ATLL patients with correlation of the level of soluble IL2Ra. Moreover, lymphomas derived from ATLL in paraffin-embedded tissue sections were strongly and specifically stained by CADM1 antibody, suggesting that CADM1 is one of very useful markers for identifying various types of ATLL cells.

Authors’ Affiliations

Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
Miyakonojo National Hospital, Miyazaki, Japan
Department of Hematology, Imamura Bun-in Hospital, Kagoshima 890-0067, Japan
Division of Antibody Project, Institute for Comprehensive Medical Science, Fujita Health University, Aichi, Japan


© Nakahata et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.